Before any administration

Screening Checklist

A plain-language guide to the safety questions a program should be prepared to address before ibogaine or 5-MeO-DMT administration.

This is educational context, not medical or legal advice. A checklist cannot establish whether any individual is a candidate for treatment.

Tropical outdoor setting used alongside a safety-first screening checklist

Look for a process, not a promise.

For people comparing programs, the first question is not whether a center sounds reassuring. It is whether it can explain a structured screening process, its limits, and the reasons some risks require postponement, referral, or a different level of care. The broader ibogaine and 5-MeO-DMT safety brief gives useful background for putting those conversations in context.

Screening practices can vary by jurisdiction and program. Readers evaluating ibogaine therapy for PTSD questions should be especially careful not to treat a program’s therapeutic framing as proof that a particular risk has been resolved. A clear process should distinguish uncertainty from reassurance.

History reviewed

Ask what medical, psychiatric, medication, and substance-use history is considered before a decision is made.

Findings explained

Expect plain language about what a result or disclosed history could mean for safety planning and eligibility.

Emergency readiness

Ask how the setting handles deterioration, transfer, monitoring, and complications rather than assuming they are covered.

Consent made specific

Informed consent should cover known uncertainties, foreseeable risks, alternatives, and the right to ask questions.

Cardiovascular history and ECG/QTc questions

For ibogaine, cardiovascular screening deserves direct, detailed questions. A program should be able to describe how it reviews cardiac history, fainting or palpitations, family history that may matter, and medication exposures that could affect cardiac rhythm. The FDA’s discussion of QT-related rhythm risk illustrates why a drug’s potential to affect cardiac electrical activity is treated seriously in medication safety generally.

Because ibogaine has been associated with QT interval concerns, it is reasonable to ask whether an ECG is part of the review, how QTc findings are interpreted, and who makes that assessment. The goal is not to self-interpret a tracing; it is to find out whether the program has a transparent, individualized evaluation pathway. Questions about ibogaine’s legal status in the United States are separate from questions about a center’s screening standards.

Location does not substitute for clinical scrutiny. Whether someone is considering ibogaine treatment options in Utah or a program elsewhere, the safety question remains the same: what specific cardiovascular information is reviewed, and how are concerns escalated?

Sunlit resort landscape accompanying the cardiovascular screening discussion

Psychiatric context and medication flags

Both ibogaine and 5-MeO-DMT warrant a careful conversation about psychiatric history, including past or current psychosis, mania, severe destabilization, and suicidality. Programs should not make this a perfunctory intake item. They should explain what they ask, what support is available when someone discloses acute concerns, and where their own boundaries are.

Medication review is equally important. Readers should expect direct discussion of SSRIs, MAOIs, QT-prolonging drugs, and other prescribed, nonprescribed, or recently used substances that could matter. The National Institute of Mental Health’s suicide-prevention guidance underscores the importance of taking suicidal thoughts or behavior seriously rather than treating them as background information.

It is also useful to understand the general concept of drug interaction: a risk assessment may involve combinations, timing, dose history, and individual health factors, not merely a yes-or-no medication list. A center should make clear that stopping or changing medication requires appropriate professional guidance, not a checklist alone.

Withdrawal timing, breathing, and aspiration risk

Substance withdrawal timing can materially change the risk picture. A responsible intake discussion should cover recent alcohol, opioid, benzodiazepine, stimulant, and other substance use; withdrawal symptoms; and whether the proposed setting is equipped for what might occur. The reason for asking is not to impose a universal timeline, but to make visible how a program evaluates instability and interaction risk.

Programs should also ask about pulmonary and aspiration-related factors: breathing disorders, respiratory illness, vomiting history, swallowing concerns, sleep-related breathing problems, and any conditions that could affect airway safety or monitoring. For background on why aspiration is a serious clinical event, see the National Library of Medicine overview of aspiration pneumonitis and pneumonia.

For readers comparing destinations, the discussion should remain specific. A description of ibogaine treatment in Europe may help frame regional differences, but it cannot answer what a particular facility actually assesses before administration.

Consent should be understandable, voluntary, and specific.

Informed consent is more than a signature. Readers should expect time to ask about the intended substance, route and setting of administration, foreseeable harms, uncertainty in the evidence, alternatives, monitoring, and what happens if they decide not to proceed. If a center cannot explain how ibogaine is administered in clear terms, that is a useful signal to slow down and ask more questions.

Clarity also means distinguishing program marketing from regulatory reality. A Mexico retreat program may use its own vocabulary for support and supervision, while the actual screening process, emergency capacity, and legal framework still need direct verification. The same caution applies when reviewing ibogaine centers in Mexico: ask each provider what it does, who is responsible for each step, and how it handles a changed risk assessment.

Practical screening questions

What should a screening conversation clarify before ibogaine or 5-MeO-DMT?

It should make the screening process understandable: what history is reviewed, what testing or records may be requested, what medication and withdrawal questions are asked, how risk decisions are made, and what emergency response capability is available. The broader safety primer can help readers organize these topics before speaking with a provider.

Why is an ECG and QTc discussion especially relevant to ibogaine?

Ibogaine has been associated with cardiac rhythm risk, including QT interval concerns. A prospective program should be able to explain whether and how cardiac history, ECG findings, medication exposure, and other risk factors are reviewed. This is a conversation about process and risk rationale, not a substitute for medical interpretation.

Can a checklist replace medical assessment?

No. This page is educational and does not determine eligibility, diagnose conditions, or replace individualized evaluation by an appropriately qualified clinician or applicable regulatory guidance. The site’s emergency protocol context is another useful prompt for asking what would happen if a concern emerges before or during a program.

Verify the practice, not the impression.

Before committing to a program, ask providers to describe their actual screening steps, who reviews concerns, what records or tests they require, and how they coordinate escalation or emergency care. If answers are vague, rushed, or inconsistent, pause and seek clearer information.

For a fuller explanation of how this independent resource approaches risk, evidence limits, and careful decision-making, see the purpose behind Bright Basin 55. Regulatory requirements and provider capabilities can differ, so direct verification with providers and relevant regulators remains essential.